United Therapeutics Corporation (BMV:UTHR)
Mexico
· Delayed Price · Currency is MXN | Market Cap | 379.98B |
| Revenue (ttm) | 57.30B |
| Net Income (ttm) | 24.03B |
| Shares Out | n/a |
| EPS (ttm) | 501.57 |
| PE Ratio | 15.81 |
| Forward PE | 16.43 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 34 |
| Average Volume | 593 |
| Open | 8,062.17 |
| Previous Close | n/a |
| Day's Range | 8,062.17 - 8,062.17 |
| 52-Week Range | 5,672.39 - 8,085.00 |
| Beta | n/a |
| RSI | n/a |
| Earnings Date | Feb 25, 2026 |
About United Therapeutics
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitr... [Read more]
Financial Performance
In 2025, United Therapeutics's revenue was $3.18 billion, an increase of 10.61% compared to the previous year's $2.88 billion. Earnings were $1.33 billion, an increase of 11.68%.
Financial numbers in USDNews
These Analysts Increase Their Forecasts On United Therapeutics After Upbeat Q4 Earnings
United Therapeutics Corp (NASDAQ: UTHR) reported better-than-expected earnings for the fourth quarter on Wednesday.
United Therapeutics Q4 Earnings: Sky May Be The Limit For This Management Team
United Therapeutics Corporation delivered strong Q4 and FY2025 results, with revenues up 10%+ and net income per share up ~14%, driving a >75% stock rally. UTHR's Tyvaso remains the dominant PAH franc...
United Therapeutics Corporation (UTHR) Q4 2025 Earnings Call Transcript
United Therapeutics Corporation (UTHR) Q4 2025 Earnings Call Transcript
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2025 Financial Results
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ...
United Therapeutics Corporation to Present at the TD Cowen 46th Annual Health Care Conference
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that Michael Benkowitz, President and Chief Operating Officer, will p...
United Therapeutics Corporation to Report Fourth Quarter and Full Year 2025 Financial Results Before the Market Opens on Wednesday, February 25, 2026
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its fourth quarter and full year 2025 financial r...
United Therapeutics Announces Positive Results from Phase 1 Study of miroliverELAP® in Patients with Acute Liver Failure
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) today announced positive results from its phase 1 study of miroliverELAP®, an externa...
United Therapeutics Corporation Announces Appointment of Kevin J. Tracey to its Board of Directors
SILVER SPRING, Md. & DURHAM, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company's Board of Directors appointed Kevin ...
United Therapeutics Corporation (UTHR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
United Therapeutics Corporation (UTHR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
United Therapeutics Corporation to Present at the 44th Annual J.P. Morgan Healthcare Conference
SILVER SPRING, Md. & DURHAM, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that Dr. Martine Rothblatt, Chairperson and Chief Executive Officer, will present a c...
Flurry of Bullish Inflows Sends United Therapeutics Higher
United Therapeutics Corporation (UTHR) shares up 3,603% since Big Money first bought big in 2004.
United Therapeutics Corporation (UTHR) Presents at Jefferies London Healthcare Conference 2025 Transcript
United Therapeutics Corporation ( UTHR) Jefferies London Healthcare Conference 2025 November 18, 2025 7:00 AM EST Company Participants Harrison Silvers - Manager of Investor Relations James Edgemond ...
United Therapeutics Corporation (UTHR) Presents at UBS Global Healthcare Conference 2025 Transcript
United Therapeutics Corporation ( UTHR) UBS Global Healthcare Conference 2025 November 10, 2025 9:30 AM EST Company Participants Patrick Poisson - Executive VP of Technical Operations Conference Call...
United Therapeutics Corporation to Present at Upcoming Investor Conferences
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that company executives will provide a...
United Therapeutics Corporation Announces First Transplant in EXPAND Clinical Trial of UKidney in Patients With End-Stage Renal Disease
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) today announced the first clinical xenotransplantation in its EXPAND study of the UKi...
United Therapeutics Corporation (UTHR) Q3 2025 Earnings Call Transcript
United Therapeutics Corporation ( UTHR) Q3 2025 Earnings Call October 29, 2025 9:00 AM EDT Company Participants Harrison Silvers - Manager of Investor Relations Martine Rothblatt - Founder, Chairman ...
United Therapeutics Corporation Reports Record Third Quarter 2025 Financial Results
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced record financial results for the quart...
United Therapeutics Corporation to Report Third Quarter 2025 Financial Results Before Market Open on Wednesday, October 29, 2025
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2025 financial results before t...
United Therapeutics to Feature Clinical Data at the CHEST 2025 Annual Meeting
SILVER SPRING, Md., & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced two presentations at the upcoming CHE...
United Therapeutics Corporation - Special Call
United Therapeutics Corporation - Special Call Company Participants Harrison Silvers - Manager of Investor Relations Leigh Peterson - Executive Vice President of Product Development & Xenotransplantat...
United Therapeutics Corporation (UTHR) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript
United Therapeutics Corporation (NASDAQ:UTHR) Bernstein 2nd Annual Global Healthcare Conference September 23, 2025 1:10 PM EDT Company Participants Harrison Silvers Martine Rothblatt - Founder, Chair...
United Therapeutics Corporation to Review Data from the Successful TETON-2 Pivotal Study of Nebulized Tyvaso® in Idiopathic Pulmonary Fibrosis
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will host a webcast to review data from the successful TETON-...
United Therapeutics Corporation to Present at the Bernstein 2nd Annual Healthcare Forum
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Martine Rothblatt, Ph.D., Chairpe...
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the European Respiratory Society Congress
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that recent research across its commer...